Business
ILUMYA® (tildrakizumab) Pen (Auto-Injector) Now Available for Canadians Living with Moderate-to-Severe Plaque Psoriasis
Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased to announce the availability of ILUMYA (tildrakizumab) Pen, a self-administered auto-injector treatment option for adults living with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
About this update from Sun Pharmaceutical Industries Limited
[{"type":"text","content":"The ILUMYA Pen offers eligible patients a safe and effective treatment option that supports ease of use and may help reduce clinical visits through self-administration","length":172,"tagName":"p","attribs":{}},{"type":"text","content":"MUMBAI, India and BRAMPTON, ON, Jan. 7, 2026 /CNW/ - Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased to announce the availability of ILUMYA (tildrakizumab) Pen, a self-administered auto-injector treatment option for adults living with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.","length":407,"tagName":"p"},{"type":"image","alt":"Sun Pharma Canada Inc. logo (CNW Group/Sun Pharma Canada Inc.)","displaySize":"","headline":null,"caption":"Sun Pharma Canada Inc. logo (CNW Group/Sun Pharma Canada Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":296,"height":400,"url":"https://media.zenfs.com/en/cnwgroup.com/613face4f0fef50f3812632c775928fc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TAdSriONgJZEnhD9f0u.RQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU2ODtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/613face4f0fef50f3812632c775928fc","width":296,"height":400}},"href":"https://mma.prnewswire.com/media/2855830/Sun_Pharma_Canada_Inc__ILUMYA___tildrakizumab__Pen__Auto_Injecto.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""The approval of the ILUMYA Pen further exemplifies Sun Pharma's commitment to addressing the unmet needs that are important to the patients we serve," said Richard Ascroft, North America CEO, Sun Pharma. "We know that people living with moderate-to-severe plaque psoriasis need safe and effective treatment options but they also deserve easy-to-use treatment options that can improve quality of life. With the launch of the ILUMYA Pen, Canadians can now access their trusted therapy in a delivery device that works best for them."","length":555,"tagName":"p"},{"type":"text","content":"The ILUMYA Pen was engineered to meet the needs of patients with moderate-to-severe plaque psoriasis. Its three-month dosing schedule, combined with the convenience of a self-administered auto-injector Pen supports patient adherence and quality of life, without requiring significant lifestyle adjustments...